A Phase II Study of Pioglitazone for Patients With Cancer of the Pancreas

Status Completed

Clinical Trial Summary

This study is being done to determine whether or not addition of the oral medication, pioglitazone to standard chemotherapy, results in improvement of blood tests that measure the body's ability to utilize sugar (glucose and insulin metabolism). In addition the investigators want to determine whether or not treatment with pioglitazone results in (1) improvement in the size of the tumor, (2) weight gain, (3) improved ability to function during the day and (4) quality of life.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01838317
Study type	Interventional
Source	University of Texas Southwestern Medical Center
Contact
Status	Completed
Phase	Phase 2
Start date	May 2013
Completion date	September 20, 2017

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT01313416` - Gemcitabine and CT-011 for Resected Pancreatic Cancer	Phase 2
Recruiting	`NCT03323944` - CAR T Cell Immunotherapy for Pancreatic Cancer	Phase 1
Terminated	`NCT02669914` - MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors	Phase 2
Withdrawn	`NCT04123574` - A Pilot Study of BXCL701 in Patients With Pancreatic Cancer	Early Phase 1
Active, not recruiting	`NCT02905578` - A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)	Phase 2
Completed	`NCT01446458` - Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer	Phase 1
Recruiting	`NCT05252390` - NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors	Phase 1/Phase 2
Completed	`NCT02311361` - Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer	Phase 1/Phase 2
Completed	`NCT02681796` - Epidural Analgesia Use in Pancreatic Resections	Phase 1
Terminated	`NCT02608229` - BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer	Phase 1
Completed	`NCT03883919` - Liposomal Irinotecan Plus 5-FU / LV Combined With Paricalcitol in Patients With Advanced Pancreatic Cancer Progressed on Gemcitabine-based Therapy	Phase 1
Terminated	`NCT03122106` - Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy	Phase 1
Terminated	`NCT00613730` - Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint	Phase 2
Terminated	`NCT02950025` - Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies	Phase 2
Recruiting	`NCT03821025` - Self-expandable Metal Stents Versus Multiple Plastic Stents for Palliation of Biliary Obstruction	N/A
Completed	`NCT04542291` - Targeting Pancreatic Cancer With Sodium Glucose Transporter 2 (SGLT2) Inhibition	Phase 1
Terminated	`NCT03956056` - Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy	Phase 1
Recruiting	`NCT05975593` - MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial
Active, not recruiting	`NCT05111353` - Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery	Phase 1
Terminated	`NCT02352831` - Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma	Phase 1/Phase 2